ISSN 1662-4009 (online)

ey0021.9-12 | Thyroid Issues in Cancer Survivors | ESPEYB21

9.12. Risk of second primary thyroid cancer in cancer survivors

Y Yuan , P Sun , H Xiao , L Li , J Li , X Ai

Brief Summary: This retrospective study evaluated the risk and clinicopathological features of second primary thyroid cancer (SPTC) in cancer survivors. The Surveillance, Epidemiology, and End Results (SEER) Program collected cancer incidence and mortality data from 8 population-based registries. They identified 7066 patients with SPTC and 83,113 patients with primary thyroid cancer (TC). The standardized incidence ratio (SIR) of SPTC in cancer survivors was higher than in the...

ey0015.8-8 | Important for Clinical Practice | ESPEYB15

8.8 Noninvasive prenatal diagnosis of 21-hydroxylase deficiency using target capture sequencing of maternal plasma DNA

D Ma , Y Yuan , C Luo , Y Wang , T Jiang , F Guo , J Zhang , C Chen , Y Sun , J Cheng , P Hu , J Wang , H Yang , X Yi , W Wang , Asan , Z Xu

To read the full abstract: Sci Rep. 2017; 7(1): 7427Prenatal dexamethasone treatment has been suggested over three decades ago to prevent virilization of a female fetus affected with 21-hydroxylase deficiency due to genetic mutations in the CYP21A2 gene. However, current treatment guidelines for CAH regard this treatment still as experimental, mainly because follow-up studies of treated fetu...